Tevogen Bio Inc.

1.10
-0.10 (-8.33%)
At close: Mar 31, 2025, 3:59 PM

Company Description

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.

Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID.

The company is based in Warren, New Jersey.

Tevogen Bio Inc.
Tevogen Bio  Inc. logo
Country United States
IPO Date Jan 5, 2022
Industry Biotechnology
Sector Healthcare
Employees 17
CEO Dr. Ryan H. Saadi M.D., M.P.H, M.P.H.

Contact Details

Address:
15 Independence Blvd
Warren, New Jersey
United States
Website https://tevogen.com

Stock Details

Ticker Symbol TVGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001860871
CUSIP Number 88165K101
ISIN Number US88165K1016
Employer ID 98-1597194
SIC Code 6770

Key Executives

Name Position
Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. Co-Founder, Chief Executive Officer & Chairman
Kirti Desai CPA Chief Financial Officer
Mittul Mehta Chief Information Officer & Head of Tevogen.ai
Dr. Neal Flomenberg M.D. Chief Scientific Officer and Global R&D Lead
Sadiq Khan M.B.A. Chief Commercial Officer
Stephen Chen M.B.A. Chief Technical Officer
Tapan V. Shah Head of Investor Relations & Corporate Development

Latest SEC Filings

Date Type Title
Mar 14, 2025 4 Filing
Mar 11, 2025 4 Filing
Mar 06, 2025 4 Filing
Jan 28, 2025 424B3 Filing
Jan 28, 2025 8-K Current Report
Dec 26, 2024 4 Filing
Dec 26, 2024 4 Filing
Dec 26, 2024 4 Filing
Dec 26, 2024 4 Filing
Dec 26, 2024 4 Filing